Quick Answer
Allarity Therapeutics, Inc. reported Operating Income of -$12.61 million for fiscal year 2025.
Allarity Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$12.61M | +53.7% |
| 2024 | -$27.24M | -59.0% |
| 2023 | -$17.13M | +50.3% |
| 2022 | -$34.46M | -29.8% |
| 2021 | -$26.56M | -219.2% |
| 2020 | -$8.32M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.52M | +79.6% | +39.1% |
| June 30, 2025 | -$4.13M | -22.6% | -36.1% |
| March 31, 2025 | -$3.04M | +28.4% | +75.3% |
| September 30, 2024 | -$12.31M | -178.2% | -265.3% |
| June 30, 2024 | -$3.37M | +18.9% | +20.5% |
| March 31, 2024 | -$4.24M | -15.6% | +4.2% |
| September 30, 2023 | -$4.43M | +3.0% | -6.5% |
| June 30, 2023 | -$4.16M | +14.2% | -13.3% |
- Allarity Therapeutics, Inc. showed an increase of +53.7% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Allarity Therapeutics, Inc.’s operating income has declined by 51.5% (from -$8.32 million to -$12.61 million).
- The most recent figure is from Allarity Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: